Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI - Trial NCT04954599
Access comprehensive clinical trial information for NCT04954599 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Maastricht University and is currently Not yet recruiting. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 126 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Maastricht University
Timeline & Enrollment
Phase 1/2
Oct 01, 2021
Oct 01, 2024
Primary Outcome
Incidence of treatment-emergent adverse events including dose-limiting toxicities,Incidence of clinically significant abnormal measurements in physical examination, vital signs, electrocardiogram (ECG), lab tests and ECOG performance status
Summary
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort
 expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor
 agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumours or tumor types with
 high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with
 solid tumour and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a
 phase I-IIa clinical trial
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04954599
Non-Device Trial